Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (NASDAQ: PSNL) is a Fremont, California-based medical laboratories company focused on advanced genomics for precision oncology. The Personalis news stream centers on developments in molecular residual disease (MRD) testing, circulating tumor DNA (ctDNA) analysis, and ultra-comprehensive genomic profiling for cancer management.
News about Personalis often highlights clinical and scientific milestones for its NeXT Personal MRD platform, including publications in journals such as Clinical Cancer Research, Cell, Nature Medicine, and Annals of Oncology as referenced in company communications. These articles describe how NeXT Personal is used to detect very small traces of ctDNA, monitor treatment response, and predict outcomes across solid tumors, including breast cancer and non-small cell lung cancer.
Investors and clinicians following PSNL can expect updates on Medicare coverage decisions for NeXT Personal tests, reimbursement rate determinations, and coverage expansions for indications such as breast cancer surveillance. Press releases also cover collaborations with biopharma companies and academic centers, including trials like TRACERx, NeoADAURA, and LAURA, where Personalis’ assays are applied to assess residual disease, relapse risk, and therapy response.
Additional news items include quarterly and annual financial results, preliminary performance updates, and disclosures related to the company’s "Win-in-MRD" commercial strategy and clinical test volume trends. Corporate announcements such as participation in healthcare conferences, inducement equity grants under Nasdaq rules, and amendments to commercialization agreements with partners like Tempus AI, Inc. are also part of the PSNL news flow.
By reviewing Personalis news, readers can track how the company’s MRD and precision oncology platforms are being adopted in clinical practice and research, as well as monitor key regulatory, reimbursement, and partnership developments that shape its role in cancer genomics.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, announced its participation in upcoming investor conferences. The company will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10, 2020, at 4:15 p.m. ET. Additionally, it will participate in the Oppenheimer Fall MedTech Summit on November 12, 2020. Personalis focuses on providing comprehensive molecular data through its ImmunoID NeXT Platform, aimed at enhancing cancer therapy development. The firm is also involved in the VA Million Veterans Program to sequence veteran genomes.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will release its Q3 2020 financial results on November 5, 2020, post-market. A conference call and webcast will be held at 2:00 PM PT / 5:00 PM ET to discuss these results and recent developments. The company specializes in advanced genomic solutions for cancer, utilizing its ImmunoID NeXT Platform to analyze 20,000 human genes and immune responses from patient samples. Personalis is also partnering with the VA Million Veterans Program to sequence over two million veteran genomes.
Personalis, Inc. (Nasdaq: PSNL) announced its participation at the Immuno Series US Virtual meeting on October 15-16, 2020. The company will present on maximizing biomarker discovery using its ImmunoID NeXT™ platform. Dr. Kedar Hastak will address challenges in immuno-oncology research and how enhanced biomarker analysis can inform combinatorial immunotherapy. The platform integrates DNA and RNA sequencing for a comprehensive cancer characterization, showcasing case studies that reveal insights into tumor biology and treatment efficacy.
Personalis, Inc. (Nasdaq: PSNL) announced its participation in the online conference IO Combinations 360˚ on October 1-2, 2020. Dr. Travis Yates will present on the "Comprehensive immunogenomics to enable composite biomarkers for immunotherapy response using a sample sparing approach." The presentation will cover the innovative ImmunoID NeXT platform, focusing on its benefits in immuno-oncology research, including case studies from metastatic melanoma patients. Personalis aims to enhance cancer therapy development by providing detailed genomic data about patients’ cancers and immune responses.
Personalis, Inc. (Nasdaq: PSNL) announces its participation in the Digital World CB & CDx meeting from September 29 to October 1, 2020. The company will present on the ImmunoID NeXT™ platform, addressing challenges in immuno-oncology research. Dr. Kedar Hastak will highlight the platform’s ability to consolidate biomarker assays for a comprehensive view of tumor-immune interactions. Additionally, Personalis is advancing precision medicine with its NeXT Dx™ and NeXT CDx™ diagnostic initiatives. The company focuses on delivering extensive molecular data to support cancer treatment.